Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Quick facts
Marketed products
- ganagliflozin · Other
- Ozempic® · Diabetes
Ozempic activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose levels in type 2 diabetes. - Wegovy ®
Phase 3 pipeline
- CAL/BDP Gel · Dermatology
CAL/BDP Gel is a topical combination of calcipotriol (vitamin D analogue) and betamethasone dipropionate (corticosteroid) that reduces skin inflammation and normalizes keratinocyte differentiation. - HDG1901
HDG1901 is an investigational drug in Phase 3 development by Hangzhou Zhongmei Huadong Pharmaceutical, but its specific mechanism of action is not publicly disclosed. - HDM1002 200mg, oral, once daily, 52 weeks
HDM1002 is a small molecule inhibitor that targets a specific molecular pathway involved in metabolic or inflammatory disease. - HDM1002 400mg, oral, once daily, 52 weeks
HDM1002 is a small molecule inhibitor that targets a specific molecular pathway involved in metabolic or inflammatory disease. - HDM1002 placebo, oral, once daily, 52 weeks
- HDM1005 1
HDM1005 1 is a small molecule drug. - HDM1005 2
HDM1005 2 is a small molecule drug with an unknown mechanism of action. - HDM1702 · Oncology
HDM1702 is a small molecule inhibitor targeting a specific molecular pathway in development for oncology indications. - MB-102 DMID · Oncology
MB-102 DMID is a monoclonal antibody targeting CD47. - MB-102 OMID · Oncology
MB-102 OMID is a monoclonal antibody targeting CD47. - MC2-01 cream · Dermatology
MC2-01 cream is a topical corticosteroid formulation designed to reduce inflammation and provide therapeutic benefit when applied to affected skin areas. - MC2-01 vehicle
No mechanism of action is available for MC2-01 vehicle. - Roflumilast Cream 0.3% · Respiratory
Roflumilast is a phosphodiesterase-4 inhibitor, which reduces inflammation by inhibiting the production of pro-inflammatory cytokines.
Phase 2 pipeline
Phase 1 pipeline
- [14C] HDM1002
- HDM1002
- HDM1002 and itraconazole
- HDM1002 and rifampicin
- HDM2005
- HDM2006
- HDM2012
- HDM2017
- HDM2020
- Rituximab or Rituximab biosimilar
- Single dose of HDM1002 on Day 1
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI brief
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. pipeline updates RSS
Frequently asked questions about Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
What are Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.'s marketed drugs?
Top marketed products include ganagliflozin, Ozempic®, Wegovy ®.
What is Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.'s pipeline?
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. has 13 drugs in Phase 3, 2 in Phase 2, 11 in Phase 1. Late-stage candidates include CAL/BDP Gel, HDG1901, HDM1002 200mg, oral, once daily, 52 weeks, HDM1002 400mg, oral, once daily, 52 weeks.
Related
- ganagliflozin · Other
- Ozempic® · Diabetes
- Wegovy ®
- Sector hub: All tracked pharma companies